IL2 and myeloid sarcoma: Besides a Th17 dominant immune response, we could not demonstrate a definitive Th2 associated response in MOGAD and AQP4+ NMOSD analyzing serum samples, because IL-2, IL-4 and IL-13 were not increased in our population compared to MS patients.